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Lafora disease (LD), a fatal neurodegenerative disorder characterized by 
intracellular inclusions called Lafora bodies (LBs), is caused by recessive loss-of-
function mutations in the genes encoding either laforin or malin. Previous studies 
suggested a role of these proteins in regulating glycogen biosynthesis, in 
glycogen dephosphorylation and in the modulation of intracellular proteolytic 
systems. However, the contribution of each of these processes to LD 
pathogenesis is unclear. Here we review our recent finding that dysfunction of 
autophagy is a common feature of both laforin- and malin-deficient mice, 
preceding other pathological manifestations. We propose that autophagy plays a 
primary role in LD pathogenesis and is a potential target for its treatment. 
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Lafora disease. Lafora progressive myoclonus epilepsy, or LD (OMIM 
254780), is an autosomal recessive neurodegenerative disorder resulting in 
severe epilepsy and death. First described in 1911 by the Spanish neurologist 
Gonzalo Rodríguez Lafora in patients with “teenage-onset myoclonus epilepsy 
with dementia,” the presence in the cytoplasm of neurons of PAS-positive 
intracellular inclusions, nowadays called LBs, is a hallmark of this disorder. LBs 
are essentially composed of insoluble, starch-like and poorly-branched glycogen 
molecules, called polyglucans, and their very low protein content (6%) 
distinguishes LD from other neurodegenerative disorders with inclusion bodies. 
As LD progresses, patients develop dementia with apraxia, aphasia and visual 
loss, leading them to a vegetative state and death, usually within the first decade 
from the onset of the disease. Although nonneurological symptoms are rare in LD, 
LBs are found in the tissues of most patients, and it is still unclear whether they 
cause the pathology or are simply a consequence. 
To date, LD-causing mutations have been identified in two genes, EPM2A 
(60%) and EPM2B (40%), encoding respectively laforin, a dual-specificity protein 
phosphatase with a carbohydrate-binding domain, and malin, an E3 ubiquitin-
ligase. Early observations that patients carrying loss-of-function mutations in 
laforin or malin are indistinguishable, anticipated the subsequent demonstration 
that both proteins organize into a complex: the critical player in LD pathogenesis. 
However, it is still unclear how these mutations produce the disease. 
Pathogenic mechanisms in Lafora disease. Since laforin or malin 
mutations, both in humans and in animal models, correlate with accumulation of 
LBs in many tissues, it was proposed that glycogen metabolism is disturbed in 
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LD. This is supported by evidence that the laforin-malin complex downregulates 
glycogen synthase (GS) and the protein targeting subunit to glycogen (R5/PTG) 
of protein phosphatase 1 through malin-dependent ubiquitination and proteasome 
degradation. However, different studies were unable to identify alterations in the 
levels or activities of proteins implicated in glycogen metabolism, perhaps 
because its modulation by the laforin-malin complex is a subtle process. In this 
regard, it was recently shown that lowering glycogen synthesis by R5/PTG 
depletion reduces LBs, and that decreased laforin levels correlate with elevated 
glucose uptake, both observations supporting an impact of glycogen synthesis in 
LD pathogenesis.  
A remarkable observation was the recognition that laforin is a glycogen 
phosphatase. Based on these and other data it was proposed that, by 
suppressing excessive glycogen phosphorylation, laforin prevents the formation 
of LBs. Importantly, this activity does not require malin, which makes unclear the 
role of the laforin-malin complex in the process. Also, the inhibition of the activity 
of laforin by glycogen binding and the ubiquitination of laforin by malin for 
degradation are difficult to accommodate in this hypothesis. 
Finally, it has been demonstrated that, in the absence of the laforin-malin 
complex, unfolded proteins and other proteolytic substrates accumulate. Laforin 
may be acting here as an ancillary protein bringing proteasome or autophagy 
substrates to malin for ubiquitination or, upon ubiquitination, directing them to 
degradation. In addition, the laforin-malin complex may directly regulate the 
activity of the proteolytic systems (see below). 
Analysis of autophagy in laforin- and malin-deficient mice. We 
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previously observed compromised autophagosome formation in laforin-deficient 
human fibroblasts and mice (MEFs and liver) and that overexpression of laforin 
increases LC3-II levels. Therefore, we proposed that laforin activates autophagy. 
Our studies also suggested that the protein(s) responsible for this modulation 
were in the MTOR pathway, upstream of TSC1/TSC2. 
We have now extended these observations to other tissues, particularly 
brain, and to malin-deficient mice, demonstrating similar defects in autophagy. 
This is consistent with the identical phenotypes of LD patients with laforin or malin 
mutations, and illustrates that it is a lack of the laforin-malin complex, due to 
either laforin or malin loss, that impairs autophagy.  
Autophagy dysfunction precedes other pathological manifestations, 
suggesting that this event is critical in the early stages of LB formation. We, 
therefore, propose (Fig. 1) that a combination of both impaired autophagy and 
glycogen synthesis dysregulation results in the formation of LBs and in the 
neurological and behavioral abnormalities of LD. This is likely exacerbated, when 
laforin is lacking, by uncontrolled glycogen hyperphosphorylation.  
Future research. If our interpretations are correct, impaired autophagy 
would be one of the primary causes of accumulation of polyglucans in LBs. 
Therefore, we will analyze in our LD mice models the therapeutic benefits of 
enhancing autophagy. 
A clear conclusion from our work is that impairment of autophagy in both 
LD mice models is a consequence of the lack of laforin-malin complexes. In this 
respect, our earlier report using laforin-deficient mice indicating that autophagy 
dysfunction could be in part explained by activation of MTOR is in apparent 
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conflict with our failure to demonstrate a similar result in brains and in malin-
deficient mice. Additional experiments will determine the precise molecular 
mechanisms underlying autophagy impairment in LD. At present, we can only 
state that autophagy dysfunction is likely due to an altered MTOR-independent 
mechanism and that the observed MTOR activation occurs only in certain tissues 
and is exclusively related to laforin-deficiency. 
While autophagy probably regulates LB formation, it is possible that other 
consequences of defective autophagy, beyond glycogen metabolism, are relevant 
in LD pathogenesis. In fact, not all neurons undergoing degeneration in LD have 
visible LBs, suggesting that they are not the cause of LD, but one of their many 
pathological manifestations. Probably, other autophagy substrates, including 
proteins, lipids and damaged mitochondria, accumulate in LD. The contribution to 
LD pathogenesis of these and other processes, like endocytosis, synaptogenesis 
and neural plasticity, potentially altered by a compromised autophagy, will be 
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Figure 1. Pathogenic mechanisms in Lafora disease  
Functions of the laforin-malin complex would be to avoid the generation of 
polyglucans or, if already formed, to prevent their accumulation, degrading them 
before they become pathogenic. Glycogen hyperphosphorylation and 
dysregulation of glycogen synthesis, produced by loss-of-function mutations in 
either laforin or malin, are two non-mutually exclusive possibilities that may 
concur together to accumulate LBs. Also, the laforin-malin complex could be 
involved in the clearance of nascent LBs and other substrates, targeting them to 
autophagy or to the ubiquitin-proteasome system (UPS). Alternatively, it could 
enhance the activities of both proteolytic systems. Concerning this, only 
autophagy is impaired in both LD mice models (laforin- and malin-deficient), and 
this alteration precedes the formation of LBs. Therefore, autophagy is a potential 
target for the pharmacological treatment of the disease, for example with drugs 
that increase an autophagic response. The figure also depicts that 
neurodegeneration can occur without detectable formation of LBs, which can 
simply be one of the manifestations of the disease and not the cause. 
 
 
 

